Texas Yale Capital Corp’s AstraZeneca AZN Stock Holding History

Texas Yale Capital Corp’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,900	Closed	-$901K	–	506
2025 Q4	$901K	Buy	4,900 +235	+5%	+$41.2K	0.03%	291
2025 Q3	$716K	Sell	4,665 -330	-7%	-$49.9K	0.02%	314
2025 Q2	$698K	Hold	4,995	–	–	0.02%	294
2025 Q1	$734K	Sell	4,995 -2,050	-29%	-$297K	0.03%	290
2024 Q4	$923K	Buy	7,045 +306	+5%	+$42.8K	0.04%	259
2024 Q3	$1.05M	Buy	6,739 +150	+2%	+$24.2K	0.05%	258
2024 Q2	$1.03M	Hold	6,589	–	–	0.05%	246
2024 Q1	$893K	Buy	6,589 +188	+3%	+$24.9K	0.04%	267
2023 Q4	$862K	Buy	6,401 +78	+1%	+$10.1K	0.04%	267
2023 Q3	$856K	Sell	6,323 -740	-10%	-$101K	0.04%	247
2023 Q2	$1.01M	Hold	7,063	–	–	0.05%	247
2023 Q1	$980K	Hold	7,063	–	–	0.05%	250
2022 Q4	$958K	Hold	7,063	–	–	0.05%	246
2022 Q3	$775K	Buy	7,063 +505	+8%	+$64.1K	0.05%	262
2022 Q2	$867K	Hold	6,558	–	–	0.06%	247
2022 Q1	$870K	Hold	6,558	–	–	0.05%	259
2021 Q4	$764K	Hold	6,558	–	–	0.04%	277
2021 Q3	$788K	Hold	6,558	–	–	0.04%	265
2021 Q2	$786K	Hold	6,558	–	–	0.04%	267
2021 Q1	$652K	Sell	6,558 -2,200	-25%	-$221K	0.04%	282
2020 Q4	$876K	Buy	8,758 +100	+1%	+$10.6K	0.06%	248
2020 Q3	$949K	Buy	8,658 +50	+0.6%	+$5.56K	0.07%	225
2020 Q2	$911K	Hold	8,608	–	–	0.07%	221
2020 Q1	$769K	Hold	8,608	–	–	0.08%	226
2019 Q4	$858K	Hold	8,608	–	–	0.06%	263
2019 Q3	$767K	Hold	8,608	–	–	0.06%	270
2019 Q2	$711K	Sell	8,608 -8,607	-50%	-$675K	0.05%	283
2019 Q1	$1.39M	Buy	17,215 +8,607	+100%	+$678K	0.06%	276
2018 Q4	$654K	Hold	8,608	–	–	0.06%	260
2018 Q3	$681K	Hold	8,608	–	–	0.06%	286
2018 Q2	$604K	Hold	8,608	–	–	0.05%	296
2018 Q1	$602K	Sell	8,608 -182	-2%	-$12.6K	0.05%	290
2017 Q4	$610K	Buy	8,790 +2,290	+35%	+$154K	0.05%	293
2017 Q3	$440K	Hold	6,500	–	–	0.04%	335
2017 Q2	$443K	Hold	6,500	–	–	0.04%	332
2017 Q1	$405K	Buy	6,500 +750	+13%	+$43.7K	0.04%	335
2016 Q4	$314K	Sell	5,750 -229	-4%	-$13K	0.03%	362
2016 Q3	$393K	Hold	5,979	–	–	0.04%	343
2016 Q2	$361K	Hold	5,979	–	–	0.04%	351
2016 Q1	$337K	Hold	5,979	–	–	0.03%	352
2015 Q4	$406K	Buy	5,979 +229	+4%	+$15K	0.04%	329
2015 Q3	$366K	Hold	5,750	–	–	0.03%	351
2015 Q2	$366K	Hold	5,750	–	–	0.03%	382
2015 Q1	$393K	Buy	5,750 +245	+4%	+$17K	0.03%	378
2014 Q4	$387K	Hold	5,505	–	–	0.03%	364
2014 Q3	$393K	Buy	+5,505	New	+$403K	0.04%	333

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Texas Yale Capital Corp's AZN Position: Q1 2026 in Review

Texas Yale Capital Corp sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 4,900 shares — an estimated $901K sold.

Texas Yale Capital Corp first reported a position in AZN in Q3 2014 and held it in 46 quarters. The position peaked at $1.39M in Q1 2019. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Texas Yale Capital Corp reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Texas Yale Capital Corp sold 4,900 AstraZeneca shares in Q1 2026, an estimated $901K.
Texas Yale Capital Corp first reported a position in AstraZeneca in Q3 2014 and held it in 46 quarters.
Texas Yale Capital Corp's AstraZeneca position peaked at $1.39M in Q1 2019.
1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Texas Yale Capital Corp's 13F filing for Q1 2026, filed 4 May 2026.